Mylan Executives Unlikely to Lose Pay Over EpiPen Issue

October 27, 2016 05:33 AM

Executives of EpiPen maker Mylan are unlikely to lose pay over the company’s $465 million settlement of allegations it overcharged Medicaid for the lifesaving drug.

Previous post
Lobbyists as Directors Test Rules for Corporate Boards October 04, 2016 03:23 PM Directors at some companies are paid to lobby for those firms or
Next post
Corporate Super PAC Contributions Trail Individuals, Study Says November 02, 2016 12:00 AM Despite legal rulings allowing companies, trade groups